LISOMUCIL ® - Carbocysteine

LISOMUCIL ® is a drug based on Carbocysteine

THERAPEUTIC GROUP: Mucolytics

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications LISOMUCIL ® - Carbocysteine

LISOMUCIL ® is successfully used in the treatment of respiratory tract diseases characterized by hypersecretion of thick and viscous mucus.

Mechanism of action LISOMUCIL ® - Carbocysteine

Carbocysteine, active ingredient of LISOMUCIL ®, is a molecule with marked mucolytic and indirect mucoregulatory activity, supported by multiple biological capacities.

More precisely, following oral intake and intestinal absorption, Carbocysteine concentrates mainly at the lung level where it performs its biological activities, modulating the synthesis of glycoproteins and sialoproteins, thus improving the rheological properties of the mucus, increasing the secretion of chlorine and consequent water content of the mucus, increasing the synthesis of immune mediators and protecting the tissues from the oxidative damage induced by reactive oxygen species.

At the end of its activity, and after making the mucus less dense and viscous, Carbocysteine is eliminated mainly through the urine.

Studies carried out and clinical efficacy

CITOPROTECTIVE EFFECTS OF CARBOCISTEIN

Cell Stress Chaperones. 2013 Apr 12.

Interesting experimental study that demonstrates how Carbocysteine can adequately protect cells from damage induced by reactive oxygen species, increasing endogenous levels of Glutathione and other antioxidants, protecting the respiratory mucosa from the harmful action of cigarette smoke

CARBOCISTEINE AND ANTI-INFLAMMATORY ACTION

Br J Pharmacol. 2010 Jul; 160 (6): 1399-407.

Study demonstrating how Carbocysteine, especially when combined with other anti-inflammatory active ingredients, can significantly improve the inflammatory pattern present in the respiratory tract of allergic patients.

CARBOCISTEINE AND CHRONIC RESPIRATORY DISEASES

Expert Opin Pharmacother. 2009 Mar; 10 (4): 693-703. doi: 10.1517 / 14656560902758343.

clinical work that demonstrates how Carbocysteine can be successfully used in the treatment and management of chronic-obstructive respiratory diseases, being effective not so much for the mucolytic as for the antioxidant and anti-inflammatory effect.

Method of use and dosage

LISOMUCIL ®

750 mg syrup of Carbocysteine per 15ml of product;

100 mg syrup of Carbocysteine per 5 ml of product;

Granules for oral solution of 1.5 g of Carbocysteine.

Dosages and timing of intake for Carbocysteine should be defined by the physician based on the patient's overall health status, age, and the severity of the clinical picture.

In adults it is advisable to divide the entire dosage into 3 daily administrations spaced from each other for at least 8 hours.

Warnings LISOMUCIL ® - Carbocisteina

In order to avoid the occurrence of potential side effects, while maximizing the therapeutic efficacy of LISOMUCIL ®, it would be advisable to consult your doctor and assess the prescription appropriateness before starting this medicine.

Particular caution in the use of this drug should be requested for patients suffering from renal pathologies and for patients with altered expectorant abilities, for whom the increase in the volume of mucus induced by the drug could represent a potential problem.

Some pharmaceutical formats of LISOMUCIL ® may contain:

sucrose, discouraging its use in patients with diabetes, glucose-galactose malabsorption syndrome and sucrase-isomerase enzyme deficiency;
ethyl alcohol, therefore not recommended in pediatric age, in pregnant women, in alcoholics and in all those who must drive or use machinery;
parahydroxybenzoates, excipients with strong allergizing power.

It is therefore advisable to consult your doctor also for the appropriate choice of format.

PREGNANCY AND BREASTFEEDING

LISOMUCIL ® is generally contraindicated during pregnancy and in the subsequent breastfeeding period, given the lack of studies able to clarify the safety profile of Carbocysteine for fetal health.

Interactions

Pharmacological interactions are not known at the moment such as to alter the safety and efficacy profile of Carbocysteine, so as to increase the clinical risk.

Contraindications LISOMUCIL ® - Carbocysteine

The use of LISOMUCIL ® is contraindicated in patients hypersensitive to the active substance or to one of its excipients and in patients with gastro-duodenal ulcer.

Undesirable effects - Side effects

The use of Carbocisteina could determine the appearance of diarrhea, abdominal pain, nausea, and only rarely dizziness and dermatological and respiratory reactions due to hypersensitivity.